(Total Views: 471)
Posted On: 09/16/2019 7:06:09 PM
Post# of 154993
From old paper...
Interestingly, PRO 140 was markedly more active than RANTES in blocking HIV-1 in macrophage cultures.
Thus, PRO 140 was nearly equipotent at inhibiting HIV-1 replication in primary T cells and macrophages, the two principal cellular targets for virus infection in vivo. In contrast, when tested against the same virus isolates, RANTES was far less effective in blocking macrophage infection.
In another novel finding, PRO 140 and RANTES were shown to inhibit certain R5X4 viruses.
To our knowledge, this is the first reported inhibition of R5X4 virus replication on normal PBMCs by a CCR5-targeting agent.
It was unexpected that PRO 140, a weak CCR5 antagonist, would possess breadth and potency of antiviral activity as great as or greater than those of RANTES, an agonist capable of downregulating CCR5
https://jvi.asm.org/content/75/2/579
Interestingly, PRO 140 was markedly more active than RANTES in blocking HIV-1 in macrophage cultures.
Thus, PRO 140 was nearly equipotent at inhibiting HIV-1 replication in primary T cells and macrophages, the two principal cellular targets for virus infection in vivo. In contrast, when tested against the same virus isolates, RANTES was far less effective in blocking macrophage infection.
In another novel finding, PRO 140 and RANTES were shown to inhibit certain R5X4 viruses.
To our knowledge, this is the first reported inhibition of R5X4 virus replication on normal PBMCs by a CCR5-targeting agent.
It was unexpected that PRO 140, a weak CCR5 antagonist, would possess breadth and potency of antiviral activity as great as or greater than those of RANTES, an agonist capable of downregulating CCR5
https://jvi.asm.org/content/75/2/579
(0)
(0)
